scholarly journals The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer

2017 ◽  
Author(s):  
Aurelio Bartolome Castrellon ◽  
Ihor Pidhorecky ◽  
Vicente Valero ◽  
Luis Estuardo Raez
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Triple Negative ◽  
Response Rate ◽  
Pathologic Response ◽  
Chemotherapy Treatment ◽  
Improved Outcomes ◽  
Selection Of Patients ◽  
Selection Of ◽  
Made In

Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT.

scholarly journals Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Oncotarget ◽  
2018 ◽  
Vol 9 (41) ◽  
pp. 26406-26416 ◽  
Author(s):  
Angela Santonja ◽  
Alfonso Sánchez-Muñoz ◽  
Ana Lluch ◽  
Maria Rosario Chica-Parrado ◽  
Joan Albanell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Response Rate ◽  
Complete Response Rate ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Cancer Subtypes ◽  
Pathologic Complete Response Rate

Role of MR Imaging in the Selection of Patients with Early Cervical Carcinoma for Fertility-preserving Surgery: Initial Experience

Radiology ◽  
1999 ◽  
Vol 212 (2) ◽  
pp. 395-399 ◽  
Author(s):  
P. Delia Peppercorn ◽  
Arjun R. Jeyarajah ◽  
Robert Woolas ◽  
John H. Shepherd ◽  
David H. Oram ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Cervical Carcinoma ◽  
Initial Experience ◽  
Selection Of Patients ◽  
Selection Of

Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy

2017 ◽  
Vol 15 (2) ◽  
pp. e267-e273 ◽  
Author(s):  
Marco Moschini ◽  
Francesco Soria ◽  
Tobias Klatte ◽  
Gregory J. Wirth ◽  
Mehmet Özsoy ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Preoperative Risk ◽  
Selection Of Patients ◽  
Risk Grouping ◽  
Selection Of

Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients

2021 ◽  
Author(s):  
Mukur Dipi Ray ◽  
Suryanarayana S.V. Deo ◽  
Lalit Kumar ◽  
Manish Kumar Gaur
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
Advanced Stages ◽  
Selection For ◽  
Selection Of Patients ◽  
Selection Of

In cases of ovarian carcinoma, primary cytoreductive surgery (CRS) is the standard treatment up to stage IIIB, but patient selection for neoadjuvant chemotherapy (NACT) in selected cases is controversial. A total of 200 patients with advanced ovarian cancer were analyzed retrospectively, according to specific selection criteria. Primary CRS was performed in 95 patients (47.5%) and interval CRS after 3–6 cycles of NACT was performed in 105 patients (52.5%). After median follow-up of 35 months, 5-year overall survival was 53.7% in the upfront CRS group and 42.2% in the NACT group. Primary CRS is the standard in advanced stages of ovarian carcinoma, but in certain subset of patients, NACT is preferred. Identifying that group is challenging but feasible. Proper selection of patients is key to successful outcomes.

The Role of a Vibration Response Imaging Device in the Selection of Patients for Lung Resection Surgery

2011 ◽  
Author(s):  
Fatma Comce ◽  
Zuleyha Bingol ◽  
Esen Kiyan ◽  
Serhan Tanju ◽  
Alper Toker ◽  
...  
Keyword(s):  
Lung Resection ◽  
Vibration Response ◽  
Imaging Device ◽  
Selection Of Patients ◽  
Vibration Response Imaging ◽  
Selection Of

scholarly journals Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis

2020 ◽  
Vol 48 (10) ◽  
pp. 030006052096434
Author(s):  
Zhen-Yu Li ◽  
Zhen Zhang ◽  
Xiao-Zhong Cao ◽  
Yun Feng ◽  
Sha-Sha Ren
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis ◽  
Complete Response ◽  
Extensive Literature ◽  
Extensive Literature Search ◽  
Positive Breast Cancer

Background Triple-negative breast cancer (TNBC) is associated with higher aggressiveness and mortality than hormone-positive breast cancer because of the lack of approved therapeutic targets. Patients with TNBC who attain a pathological complete response (pCR) after neoadjuvant chemotherapy have improved survival. Platinum-based agents show promising activity in TNBC; however, their use remains controversial. We conducted a meta-analysis to assess the role of platinum-based agents in neoadjuvant chemotherapy in patients with TNBC. Methods We performed an extensive literature search of the Pubmed, Embase, and Cochrane databases. We calculated pooled odds ratios (OR) with 95% confidence intervals (CI) for the identified studies. Results Eight randomized controlled trials with 1345 patients were included in the analysis. The addition of platinum-based agents improved pCR compared with neoadjuvant therapy based on anthracyclines, cyclophosphamide, taxanes, and fluorouracil (49.1% vs. 35.9%; OR: 1.87, 95% CI: 1.23–2.86). Hematological adverse events were similar in both groups, except for more thrombocytopenia in the platinum-based group (OR: 7.96, 95% CI: 3.18–19.93). Conclusion The addition of platinum-based agents to neoadjuvant chemotherapy improved pCR rates in patients with TNBC, with a slight increase in hematological toxicities. Platinum-based agents might thus be an accessible and economically viable option in patients with TNBC.

scholarly journals Assess frailty but avoid frailtyism

2019 ◽  
Vol 21 (Supplement_L) ◽  
pp. L17-L19
Author(s):  
Cristiana Vitale ◽  
Loreena Hill
Keyword(s):  
Heart Failure ◽  
Health Care ◽  
Clinical Practice ◽  
Care Plan ◽  
Heart Failure Patients ◽  
Frailty Assessment ◽  
Limited Health ◽  
Selection Of Patients ◽  
Selection Of ◽  
Made In

Abstract The assessment of frailty in heart failure patients can help clinicians to build a tailored care plan, aimed at improving the selection of patients likely to benefit from one treatment vs. another, thereby improving outcomes. Although progress has been made in the ‘operationalization’ of frailty assessment, there is still the need to provide an improved instrument to assess frailty that is easy, quick and at the same time predictive within the setting of a busy clinical practice. Using such an ideal instrument, clinicians would be able to optimize the use of limited health care resources and avoid what has been termed ‘frailtyism’. This term, similar to ageism, can be defined as prejudice or discrimination based on the presence of frailty.

scholarly journals Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge

Cells ◽  
2019 ◽  
Vol 8 (9) ◽  
pp. 957 ◽  
Author(s):  
Milica Nedeljković ◽  
Ana Damjanović
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Treatment Options ◽  
Chemotherapy Resistance ◽  
Standard Of Care ◽  
Drug Efflux ◽  
Molecular Signatures ◽  
Chemotherapy Treatment ◽  
Multiple Signaling

Triple-negative (TNBC) is the most lethal subtype of breast cancer owing to high heterogeneity, aggressive nature, and lack of treatment options. Chemotherapy remains the standard of care for TNBC treatment, but unfortunately, patients frequently develop resistance. Accordingly, in recent years, tremendous effort has been made into elucidating the mechanisms of TNBC chemoresistance with the goal of identifying new molecular targets. It has become evident that the development of TNBC chemoresistance is multifaceted and based on the elaborate interplay of the tumor microenvironment, drug efflux, cancer stem cells, and bulk tumor cells. Alterations of multiple signaling pathways govern these interactions. Moreover, TNBC’s high heterogeneity, highlighted in the existence of several molecular signatures, presents a significant obstacle to successful treatment. In the present, in-depth review, we explore the contribution of key mechanisms to TNBC chemoresistance as well as emerging strategies to overcome them. We discuss novel anti-tumor agents that target the components of these mechanisms and pay special attention to their current clinical development while emphasizing the challenges still ahead of successful TNBC management. The evidence presented in this review outlines the role of crucial pathways in TNBC survival following chemotherapy treatment and highlights the importance of using combinatorial drug strategies and incorporating biomarkers in clinical studies.

The role of multimodality imaging in the selection of patients for aortic valve repair

2015 ◽  
Vol 14 (1) ◽  
pp. 75-86 ◽  
Author(s):  
Madelien V. Regeer ◽  
Michel I.M. Versteegh ◽  
Nina Ajmone Marsan ◽  
Jeroen J. Bax ◽  
Victoria Delgado
Keyword(s):  
Aortic Valve ◽  
Multimodality Imaging ◽  
Aortic Valve Repair ◽  
Valve Repair ◽  
Selection Of Patients ◽  
Selection Of
Sign in / Sign up

Export Citation Format

Share Document